Esperion announced positive results from the Phase 2 bempedoic acid/ ezetimibe combination tablet study (1002-058). This study assessed the efficacy and safety of the bempedoic acid/ ezetimibe combination tablet compared to ezetimibe and placebo in patients with both hypercholesterolemia and type 2 diabetes. 
 
Esperion’s mission is to deliver once-daily, oral therapies that complement existing oral drugs to provide the additional LDL-C lowering that these patients need. The Phase 2 study 1002-058 demonstrated that the bempedoic acid/ ezetimibe combination tablet significantly lowered LDL-C by 40 percent compared to placebo, reduced high-sensitivity C-reactive protein by 25 percent, and had no increase in muscle-related AEs, serious adverse events, discontinuations due to AEs or elevations in liver function tests.
 
“The bempedoic acid / ezetimibe combination tablet provided 40% LDL-C lowering, 25% hsCRP reductions, and did not worsen glycemic control in patients with both hypercholesteremia and type 2 diabetes on a background of no statin therapy. These results build upon the pivotal, Phase 3 bempedoic acid / ezetimibe combination tablet data announced last August, where the majority of patients were on background statin therapy,” said Tim M. Mayleben, president and chief executive officer of Esperion. “We have increasing confidence that our convenient, once-daily, oral therapies could become an important, cost-effective treatment option for millions of patients in the U.S. who are not at their LDL-C goal.”